Literature DB >> 460945

Human malignant melanoma cell lines.

J H Pope, L Morrison, D J Moss, P G Parsons.   

Abstract

A series of 10 cell lines established from human malignant melanomas is described. The morphology varied but, in general, was epithelioid. Five produced visible melanin in culture but others produced melanin precursors. All lines were aneuploid and each had a distinctive human karyotype. One line appeared not to have the same sex as the patient but its karyotype was distinct from that of other lines.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 460945     DOI： 10.3109/00313027909061945

Source DB:  PubMed          Journal:  Pathology        ISSN： 0031-3025            Impact factor:   5.306


  15 in total

1.  Complementary expression of melanosomal antigens and constant expression of pigment-independent antigen during the evolution of melanocytic tumours.

Authors:  H Takahashi; P G Parsons; D Favier; M McEwan; G M Strutton; Y Akutsu; K Jimbow
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

2.  Clonal analysis of cytotoxic T lymphocytes (CTL) against autologous melanoma. Classification based on phenotype, specificity and inhibition by monoclonal antibodies to T cell structures.

Authors:  P Hersey; M MacDonald; S Schibeci; C Burns
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Biological and biochemical properties of a human uveal melanocyte-derived cell line.

Authors:  F L Meyskens; E B Berglund; D F Saxe; B B Fuller; L Z Pacelli; J D Hall; C G Ray
Journal:  In Vitro       Date:  1980-09

4.  Inhibition of dendrite formation in mouse melanocytes transiently transfected with antisense DNA to myosin Va.

Authors:  A J Edgar; J P Bennett
Journal:  J Anat       Date:  1999-08       Impact factor: 2.610

5.  Immunohistochemical detection of the p53 oncoprotein in tumours of melanocytic origin.

Authors:  M Yamamoto; H Takahashi
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

6.  Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Treatment of stage II melanoma with viral lysates.

Authors:  P Hersey; A Edwards; A Coates; H Shaw; W McCarthy; G Milton
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

7.  Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma. II. Effects on cell mediated cytotoxicity and leucocyte dependent antibody activity: immunological effects of VMCL in melanoma patients.

Authors:  P Hersey; A Edwards; G D'Alessandro; M MacDonald
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

8.  Enhancement of cytotoxic and proliferative responses of lymphocytes from melanoma patients by incubation with monoclonal antibodies against ganglioside GD3.

Authors:  P Hersey; M MacDonald; C Burns; D A Cheresh
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

9.  Malignancy without immortality? Cellular immortalization as a possible late event in melanoma progression.

Authors:  Julia K Soo; Alastair D Mackenzie Ross; David M Kallenberg; Carla Milagre; W Heung Chong; Jade Chow; Lucy Hill; Stacey Hoare; Rebecca S Collinson; Mehnaz Hossain; W Nicol Keith; Richard Marais; Dorothy C Bennett
Journal:  Pigment Cell Melanoma Res       Date:  2011-04-20       Impact factor: 4.693

10.  Effect of novel marine nutraceuticals on IL-1α-mediated TNF-α release from UVB-irradiated human melanocyte-derived cells.

Authors:  Visalini Muthusamy; Lynn D Hodges; Theodore A Macrides; Glen M Boyle; Terrence J Piva
Journal:  Oxid Med Cell Longev       Date:  2011-09-22       Impact factor: 6.543
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.